SFM
TEVA icon

Spartan Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Spartan Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$3.27M Hold
148,300
– – 10.91% 1
2024
Q3 		$2.67M Hold
148,300
– – 8.06% 1
2024
Q2 		$2.41M Buy
148,300
+200
+0.1% +$3.08K 6.77% 1
2024
Q1 		$2.09M Buy
148,100
+4,900
+3% +$61.8K 4.27% 5
2023
Q4 		$1.5M Hold
143,200
– – 1.84% 20
2023
Q3 		$1.46M Sell
143,200
-1,077
-0.7% -$10K 1.1% 41
2023
Q2 		$2.16M Buy
144,277
+2,477
+2% +$20.1K 0.52% 68
2023
Q1 		$1.25M Buy
141,800
+6,200
+5% +$61.3K 0.58% 60
2022
Q4 		$1.27M Buy
135,600
+15,500
+13% +$135K 0.46% 78
2022
Q3 		$968K Buy
120,100
+8,600
+8% +$76K 0.29% 157
2022
Q2 		$838K Buy
+111,500
New +$971K 0.18% 224

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Spartan Fund Management's TEVA Position: Q4 2024 in Review

Spartan Fund Management held its Teva Pharmaceuticals (TEVA) position steady in Q4 2024 at 148,300 shares worth $3.27M. The position accounts for 10.91% of the portfolio, ranked #1.

Spartan Fund Management first reported a position in TEVA in Q2 2022 and has held it in 11 quarters since. 583 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Spartan Fund Management held 148,300 shares of Teva Pharmaceuticals worth $3.27M as of Q4 2024.
  • Spartan Fund Management left its Teva Pharmaceuticals share count unchanged in Q4 2024.
  • Teva Pharmaceuticals made up 10.91% of Spartan Fund Management's portfolio in Q4 2024, its #1 holding.
  • Spartan Fund Management first reported a position in Teva Pharmaceuticals in Q2 2022 and has held it in 11 quarters since.
  • 583 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Spartan Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.